Literature DB >> 23397451

NK and MSCs crosstalk: the sense of immunomodulation and their sensitivity.

Javier G Casado1, R Tarazona, F M Sanchez-Margallo.   

Abstract

Several clinical trials are currently evaluating the safety and efficacy of mesenchymal stem cells (MSCs) in different diseases. The MSCs are guided by inflammatory mediators and specific interactions with immune cells occur, especially between MSCs and the cells of the innate immune system. At the present many of these interactions remain to be determined. This review summarizes the current knowledge in relation to the susceptibility of MSCs to NK cell mediated lysis as well as the immunomodulatory activity of MSCs and its control over NK cell function. Here we hypothesize that the inflammatory context will regulate the outcome of NK-MSC interactions.

Mesh:

Substances:

Year:  2013        PMID: 23397451     DOI: 10.1007/s12015-013-9430-y

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  45 in total

1.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells.

Authors:  Ida Rasmusson; Olle Ringdén; Berit Sundberg; Katarina Le Blanc
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

Review 2.  Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications.

Authors:  Erika Deak; Erhard Seifried; Reinhard Henschler
Journal:  Int Rev Immunol       Date:  2010-10       Impact factor: 5.311

3.  Interactions between human mesenchymal stem cells and natural killer cells.

Authors:  Panagiota A Sotiropoulou; Sonia A Perez; Angelos D Gritzapis; Constantin N Baxevanis; Michael Papamichail
Journal:  Stem Cells       Date:  2005-08-11       Impact factor: 6.277

4.  Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells.

Authors:  Ignazia Prigione; Federica Benvenuto; Paola Bocca; Luca Battistini; Antonio Uccelli; Vito Pistoia
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

5.  Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes.

Authors:  Anna Krasnodembskaya; Gianluca Samarani; Yuanlin Song; Hanjing Zhuo; Xiao Su; Jae-Woo Lee; Naveen Gupta; Mario Petrini; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-03-16       Impact factor: 5.464

6.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

7.  Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery.

Authors:  Massimo Giuliani; Noufissa Oudrhiri; Zaeem M Noman; Amelia Vernochet; Salem Chouaib; Bruno Azzarone; Antoine Durrbach; Annelise Bennaceur-Griscelli
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

8.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

9.  MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2.

Authors:  Grazia Maria Spaggiari; Heba Abdelrazik; Flavio Becchetti; Lorenzo Moretta
Journal:  Blood       Date:  2009-04-27       Impact factor: 22.113

Review 10.  Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders.

Authors:  Senming Zhao; Rebekka Wehner; Martin Bornhäuser; Ralf Wassmuth; Michael Bachmann; Marc Schmitz
Journal:  Stem Cells Dev       Date:  2010-05       Impact factor: 3.272

View more
  16 in total

1.  Prospectively defined murine mesenchymal stem cells inhibit Klebsiella pneumoniae-induced acute lung injury and improve pneumonia survival.

Authors:  Holger Hackstein; Anne Lippitsch; Philipp Krug; Inna Schevtschenko; Sabine Kranz; Matthias Hecker; Kristina Dietert; Achim D Gruber; Gregor Bein; Cornelia Brendel; Nelli Baal
Journal:  Respir Res       Date:  2015-10-06

2.  Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Function of Allogeneic Activated Vγ9Vδ2 T Lymphocytes In Vitro.

Authors:  Xiaohuan Liu; Ting Feng; Tianxiang Gong; Chongyang Shen; Tingting Zhu; Qihong Wu; Qiang Li; Hong Li
Journal:  Biomed Res Int       Date:  2015-04-14       Impact factor: 3.411

3.  NK Cells and MSCs: Possible Implications for MSC Therapy in Renal Transplantation.

Authors:  Marlies Ej Reinders; Martin J Hoogduijn
Journal:  J Stem Cell Res Ther       Date:  2014-02-07

4.  Intrapericardial administration of mesenchymal stem cells in a large animal model: a bio-distribution analysis.

Authors:  Rebeca Blázquez; Francisco Miguel Sánchez-Margallo; Verónica Crisóstomo; Claudia Báez; Juan Maestre; Mónica García-Lindo; Alejandra Usón; Verónica Álvarez; Javier G Casado
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

5.  Immunomodulatory Potential of Human Adipose Mesenchymal Stem Cells Derived Exosomes on in vitro Stimulated T Cells.

Authors:  Rebeca Blazquez; Francisco Miguel Sanchez-Margallo; Olga de la Rosa; Wilfried Dalemans; Verónica Alvarez; Raquel Tarazona; Javier G Casado
Journal:  Front Immunol       Date:  2014-11-04       Impact factor: 7.561

Review 6.  Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment.

Authors:  Lukáš Zachar; Darina Bačenková; Ján Rosocha
Journal:  J Inflamm Res       Date:  2016-12-15

Review 7.  Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy.

Authors:  Jorge Zorzopulos; Steven M Opal; Andrés Hernando-Insúa; Juan M Rodriguez; Fernanda Elías; Juan Fló; Ricardo A López; Norma A Chasseing; Victoria A Lux-Lantos; Maria F Coronel; Raul Franco; Alejandro D Montaner; David L Horn
Journal:  World J Stem Cells       Date:  2017-03-26       Impact factor: 5.326

8.  Bone marrow derived mesenchymal stem cells ameliorate inflammatory response in an in vitro model of familial hemophagocytic lymphohistiocytosis 2.

Authors:  Handan Sevim; Yusuf Çetin Kocaefe; Mehmet Ali Onur; Duygu Uçkan-Çetinkaya; Özer Aylin Gürpınar
Journal:  Stem Cell Res Ther       Date:  2018-07-18       Impact factor: 6.832

9.  Immunomodulation by Mesenchymal Stromal Cells and Their Clinical Applications.

Authors:  Joaquin Cagliani; Daniel Grande; Ernesto P Molmenti; Edmund J Miller; Horacio L R Rilo
Journal:  J Stem Cell Regen Biol       Date:  2017-04-10

Review 10.  Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection.

Authors:  Panagiotis Mallis; Efstathios Michalopoulos; Theofanis Chatzistamatiou; Catherine Stavropoulos-Giokas
Journal:  World J Stem Cells       Date:  2020-08-26       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.